For instance, lipid-based nanoparticles delivering CRISPR/Cas9 targeting Pcsk9 achieved over 80 % editing efficiency in liver cells, which is relevant since Pcsk9 influences inflammatory responses and cardiovascular disease [190,192]. Here, PCSK9 is linked to cardiovascular disorder.